Navigation Links
Scios Inc. targets drug giants in arthritis war

Scios Inc. , a small California biotechnology company, is racing giant rivals to bring a pill to market that would displace injectable anti-inflammatory drugs and set a new standard in arthritis treatment. Scios' ambitions are much larger than its market capitalization of a little more than $1 billion. That's because the first company to commercialize an oral version of today's dominant injectable drugs could gain the lion's share of a market. //

Scios' drug has shown promise in early trials. But the size of the potential market makes it a prize that many big pharmaceuticals companies also covet. So far, Scios' prospects look good. The company's pill appears to inhibit an enzyme, known as the p38 kinase, which provokes inflammation.

Scios' lead comes in part because an earlier trailblazer, Vertex Pharmaceuticals Inc. , was forced to drop back after its lead p38 kinase inhibitor showed toxicity in high doses in some animals. There are also many competitors. They include drug giant GlaxoSmithKline, which first isolated the p38 kinase in the early 1990s. Glaxo's drug is in early stage clinical trials for rheumatoid arthritis, asthma and irritable bowel syndrome. Other rivals include Merck and Co. Inc. , Roche Holding Ltd. , Johnson and Johnson, and Amgen Inc.

Scion Inc. has completed trials in healthy humans and is now planning to test the drug in patients with rheumatoid arthritis. Most rivals have yet to reach this stage.
'"/>




Page: 1

Related medicine news :

1. South Africa Wins landmark case against pharmaceutical giants
2. Vedic vibration technology- the new cure for arthritis
3. Tai chi helps arthritis
4. Periodontitis a common problem in patients with arthritis
5. New device for discerning Osteoarthritis
6. Herbal extract aids in rheumatoid arthritis
7. Osteoarthritis and Estrogen are connected
8. Hyaluronan supplementation therapy for Knee Osteoarthritis
9. Green tea beneficial in preventing osteoarthritis
10. Leech Therapy for Osteoarthritis
11. Hydrotherapy Found to be Effective for Patients with Osteoarthritis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/8/2016)... Encinitas, CA (PRWEB) , ... February 08, 2016 ... ... study showing greater than 50% lower incidence rate of type 2 diabetes in ... national averages. ”It is time to make a change in public health,” states ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... speaking on how healthcare companies can use newly released government data on populations ... a population and intervene and capture the value they create to succeed in ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... states in the U.S. require dental technicians to be certified or obtain continuing ... industry, NADL created the “What’s In Your Mouth?” campaign to inform dentists and ...
(Date:2/7/2016)... Texas (PRWEB) , ... February 07, 2016 , ... ... new MyDecision™ program. MyDecision™ empowers employers and organizations with the tools and information ... MyDecision™ combines three elements to cut the cost of providing employee healthcare benefits ...
(Date:2/6/2016)... CA (PRWEB) , ... February 06, 2016 , ... US ... Ultimate Coaching Conference (YUCC) . This event brings together top non-profit leaders, ultimate organizations, ... Equity and Girls Ultimate”. Valerio Iani, Bay Area Disc Program Director of Youth and ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... -- The Senior Care Pharmacy Coalition (SCPC) today commended ... Jason Chaffetz (R-UT) and Ranking Member Elijah ... "Developments in the Prescription Drug Market," to examine ... abusive pharmacy benefit manager (PBM) pricing practices. ... Elijah Cummings (D-MD) are diligent, serious lawmakers committed ...
(Date:2/4/2016)... , Feb. 4, 2016  Montoya Love is recognized ... the field of Pharmaceuticals. Montoya is the Regulatory Systems ... Manufacturing and selling ... Becton Dickinson provides healthcare institutions, clinical laboratories and ... fifty countries across the globe. ...
(Date:2/4/2016)... Mettler-Toledo International Inc. (NYSE: MTD ) ... are the highlights: , Sales in local ... prior year.  Reported sales decreased 3% as currency reduced ... Net earnings per diluted share as reported (EPS) were ... Adjusted EPS was $4.65, an increase of 10% over ...
Breaking Medicine Technology: